CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...